Globus Medical's (NYSE: GMED) stock dropped 10% in the last week in the wake of the medical device maker's preliminary earnings report. Despite touting record fourth-quarter and full-year earnings with double-digit growth, investors had higher expectations -- in part, due to Globus' guidance for 2020.
Image source: Getty Images.
Globus specializes in developing and commercializing products to aid people who have musculoskeletal disorders. With more than 190 products, the company operates through two main divisions. The musculoskeletal solutions division focuses on implantable devices, therapies, and surgical instruments used for spinal, orthopedic, and neurosurgical procedures. The enabling technologies division focuses on computer-aided solutions for imaging, navigation, and robotic-assisted surgery.